Stocklytics Platform
Asset logo for symbol ENTA
Enanta Pharmaceuticals
ENTA59
$11.54arrow_drop_down2.53%-$0.30
Asset logo for symbol ENTA
ENTA59

$11.54

arrow_drop_down2.53%
Key Stats
Open$11.92
Prev. Close$11.84
EPS-5.30
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range11.46
12.13
52 Week Range8.08
17.80
Ratios
EPS-5.30
Fundamentals
Payout Ratio-
Industry average yield2.91%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

ENTAarrow_drop_down2.53%
US Healthcare Sectorarrow_drop_down0.54%
US Marketarrow_drop_down1.01%
warning

ENTA / Market

ENTA lose to the US Market which returned -1.01% over the last twenty four hours.
warning

ENTA / Healthcare Sector

ENTA lose to the US Healthcare sector which returned -0.54% over the last twenty four hours.

Enanta Pharmaceuticals (ENTA) Statistics

Enanta Pharmaceuticals Inc (ENTA) is a biotechnology company that focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. The company was founded in 1995 and is headquartered in Watertown, Massachusetts. ENTA utilizes its expertise in chemistry and biology to discover and develop novel therapeutics that can address unmet medical needs.
In terms of valuation metrics, ENTA has a market capitalization of $1.12 billion as of the latest available data. The stock is currently trading at a price-to-earnings ratio of 9.47, which is lower than the industry average. This indicates that the stock may be undervalued compared to its peers.
add Enanta Pharmaceuticals  to watchlist

Keep an eye on Enanta Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Enanta Pharmaceuticals (ENTA) stock's performance compared to its sector and the market over the past year?

Over the past year, Enanta Pharmaceuticals (ENTA) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 25.67%, Enanta Pharmaceuticals has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 60.84%, it has fallen short of the market average. This comparison highlights Enanta Pharmaceuticals 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Enanta Pharmaceuticals (ENTA) stock?

The PE ratio for Enanta Pharmaceuticals (ENTA) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Enanta Pharmaceuticals (ENTA) stock?

The Earnings Per Share (EPS) for Enanta Pharmaceuticals (ENTA), calculated on a diluted basis, is -$5.45. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Enanta Pharmaceuticals (ENTA) stock?

The operating margin for Enanta Pharmaceuticals (ENTA) is -134.58%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Enanta Pharmaceuticals (ENTA) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Enanta Pharmaceuticals (ENTA) is -$120.34M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Enanta Pharmaceuticals (ENTA) have?

Enanta Pharmaceuticals (ENTA) has a total debt of $226.17M. The net debt, which accounts for cash and cash equivalents against the total debt, is $189.79M.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media